Merck and Moderna reported a pivotal Phase 3 readout in melanoma for their personalized neoantigen mRNA regimen (Keytruda plus intismeran autogene), meeting the trial’s primary endpoint at interim analysis. The companies said the combination produced a statistically significant and clinically meaningful improvement in recurrence-free survival and also improved distant metastasis-free survival, with no new safety signals reported in the interim data.